# Sensus Healthcare, Inc.: Form 10-Q for the period ended Jun 30, 2019

- Company: [Sensus Healthcare, Inc.](/companies/srts.md) (CIK 1494891)
- Form: 10-Q
- Filed: 2019-08-12
- Accepted by EDGAR: Aug 12, 2019, 15:24 ET
- Period: 2019-06-30
- Accession: 0001213900-19-015316
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1494891/000121390019015316/f10q0619_sensushealthcareinc.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1494891/000121390019015316/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-04-01 to 2019-06-30 | $7.5m | us-gaap:Revenues |
| Revenue | 6 months, 2019-01-01 to 2019-06-30 | $12.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-04-01 to 2019-06-30 | $2.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2019-01-01 to 2019-06-30 | $4.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-04-01 to 2019-06-30 | $4.9m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2019-01-01 to 2019-06-30 | $8.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-04-01 to 2019-06-30 | $1.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-01-01 to 2019-06-30 | $3.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-04-01 to 2019-06-30 | $45.5k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-01-01 to 2019-06-30 | −$2.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 6 months, 2019-01-01 to 2019-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-04-01 to 2019-06-30 | $112.3k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-01-01 to 2019-06-30 | −$2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-04-01 to 2019-06-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2019-01-01 to 2019-06-30 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-04-01 to 2019-06-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2019-01-01 to 2019-06-30 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-04-01 to 2019-06-30 | 16,382,918 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2019-01-01 to 2019-06-30 | 16,244,635 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2019-01-01 to 2019-06-30 | −$941.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2019-01-01 to 2019-06-30 | $229.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-06-30 | $11.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-06-30 | $32.9m | us-gaap:AssetsCurrent |
| Total assets | at 2019-06-30 | $35.8m | us-gaap:Assets |
| Current liabilities | at 2019-06-30 | $6.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-06-30 | $8.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-06-30 | $27.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 15,663 characters.

*You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2018 (“Annual Report”). The statements in this discussion regarding our expectations of our future performance, liquidity and capital resources, our plans, estimates, beliefs and expectations that involve risks and uncertainties, and other non-historical statements in this discussion, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “could,” “should,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “target,” “goal,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Our actual results may differ materially from those contained in or implied by any forward-looking statements. Please see the Introductory Note and Item 1A. Risk Factors of our Annual Report, as updated in our subsequent quarterly reports filed on Form 10-Q, and in our other filings made from time to time with the SEC after the date of this report.*

### Overview

We are a medical device company that is committed to providing highly effective, non-invasive and cost-effective treatments for both oncological and non-oncological skin conditions. We use a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is a result of over a decade of dedicated research and development. We have successfully incorporated SRT into our portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. In February 2019, we received FDA clearance of our Sculptura™, a robotic radiation oncology system that provides targeted intraoperative triple-modulated radiotherapy and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, with a single dose.

### Components of our results of operations

We manage our business globally within one reportable segment, which is consistent with how our management reviews our business, prioritizes investment and resource allocation decisions and assesses operating performance.

### Results of Operations

|  | For the Three Months Ended June 30, 2019 | 2018 | For the Six Months Ended June 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| **Revenues** | $7,476,296 | $6,056,735 | $12,912,895 | $12,012,197 |
| **Cost of Sales** | 2,537,102 | 2,116,108 | 4,657,723 | 4,131,308 |
| **Gross Profit** | 4,939,194 | 3,940,627 | 8,255,172 | 7,880,889 |
| **Operating Expenses** |  |  |  |  |
| Selling and marketing | 1,995,263 | 1,960,309 | 4,525,608 | 4,175,220 |
| General and administrative | 963,641 | 913,624 | 1,976,803 | 2,255,876 |
| Research and development | 1,934,807 | 1,565,424 | 3,900,314 | 3,063,042 |
| **Total Operating Expenses** | 4,893,711 | 4,439,357 | 10,402,725 | 9,494,138 |
| **Income (Loss) From Operations** | 45,483 | (498,730) | (2,147,553) | (1,613,249) |
| **Other Income (Expense)** |  |  |  |  |
| Interest income | 66,825 | 23,590 | 138,843 | 45,612 |
| Interest expense | — | (65,511) | — | (98,926) |
| **Other Income (Expense), net** | 66,825 | (41,921) | 138,843 | (53,314) |
| **Net Income (Loss)** | $112,308 | $(540,651) | $(2,008,710) | $(1,666,563) |

### Three months ended June 30, 2019 compared to the three months ended June 30, 2018

**Revenue.** Revenue was $7,476,296 for the three months ended June 30, 2019 compared to $6,056,735 for the three months ended June 30, 2018, an increase of $1,419,561, or 23.4%. The increase in revenue was primarily attributable to an increase in sales of the higher priced SRT-100 Vision product in the current quarter.

**Cost of sales**. Cost of sales was $2,537,102 for the three months ended June 30, 2019 compared to $2,116,108 for the three months ended June 30, 2018, an increase of $420,994, or 19.9%. The increase in cost was due to increase in sales.

**Gross profit.** Gross profit was $4,939,194 for the three months ended June 30, 2019 compared to $3,940,627 for the three months ended June 30, 2018, an increase of $998,567, or 25.3%. Our overall gross profit percentage was 66.1% in the three months ended June 30, 2019 compared to 65.1% in the corresponding period in 2018. The increase in gross margin percentage was primarily due to more sales of the higher margin Vision product.

**Selling and marketing.** Selling and marketing expense was $1,995,263 for the three months ended June 30, 2019 compared to $1,960,309 for the three months ended June 30, 2018, an increase of $34,954, or 1.8%. The increase was primarily attributable to an increase in headcount offset by lower spending on marketing activities.

**General and administrative.** General and administrative expense was $963,641 for the three months ended June 30, 2019 compared to $913,624 for the three months ended June 30, 2018, an increase of $50,017, or 5.5%. The net increase in general and administrative was primarily due to professional services, partially offset by other decreases.

**Research and development.** Research and development expense was $1,934,807 for the three months ended June 30, 2019 compared to $1,565,424 for the three months ended June 30, 2018, an increase of $369,383, or 23.6%. The increase in research and development spending was primarily attributable to the SculpturaTM ramp to production.

**Other income (expense).** We incur interest expense in connection with our secured credit facility with Silicon Valley Bank and interest income from our cash and investments. Interest expense decreased in 2019 with the decrease in borrowings on the line of credit. Interest income increased due to increase in investment in debt securities.

### Six months ended June 30, 2019 compared to the six months ended June 30, 2018

**Revenue.** Revenue was $12,912,895 for the six months ended June 30, 2019 compared to $12,012,197 for the six months ended June 30, 2018, an increase of $900,698, or 7.5%. The growth in revenue was primarily attributable to an increase in product average selling price.

**Cost of sales**. Cost of sales was $4,657,723 for the six months ended June 30, 2019 compared to $4,131,308 for the six months ended June 30, 2018, an increase of $526,415, or 12.7%. The increase in cost was due to the increase in sales.

**Gross profit.** Gross profit was $8,255,172 for the six months ended June 30, 2019 compared to $7,880,889 for the six months ended June 30, 2018, an increase of $374,283, or 4.7%. Our overall gross profit percentage was 63.9% in the six months ended June 30, 2019 compared to 65.6% in the corresponding period in 2018. The decrease in gross margin percentage was primarily due to the mix of products sold.

**Selling and marketing.** Selling and marketing expense was $4,525,608 for the six months ended June 30, 2019 compared to $4,175,220 for the six months ended June 30, 2018, an increase of $350,388, or 8.4%. The increase was primarily attributable to increase in headcount.

**General and administrative.** General and administrative expense was $1,976,803 for the six months ended June 30, 2019 compared to $2,255,876 for the six months ended June 30, 2018, a decrease of $279,073, or 12.4%. The net decrease was due primarily to a non-recurring stock compensation expense of $444,000 in the first quarter of 2018, offset by an increase in professional fees.

**Research and development.** Research and development expense was $3,900,314 for the six months ended June 30, 2019 compared to $3,063,042 for the six months ended June 30, 2018, an increase of $837,272, or 27.3%. The increase in research and development spending was primarily attributable to the FDA clearance of SculpturaTM as well as ramp to production.

**Other income (expense).** We incur interest expense in connection with our secured credit facility with Silicon Valley Bank and interest income from our cash and investments. Interest expense decreased in 2019 with the decrease in borrowings on the line of credit. Interest income increased due to an increase in investment in debt securities.

### Financial Condition

Our cash, cash equivalent and investment balance increased to $16.8 million at June 30, 2019 from $15.4 million at December 31, 2018, primarily as a result of proceeds from exercised warrants for $2.7 million partially offset by cash used in operating activities of $0.9 million during the six months ended in June 30, 2019.

There were no borrowings under the revolving line of credit at June 30, 2019 or December 31, 2018.

### Liquidity and Capital Resources

### Overview

Our liquidity position and capital requirements may be impacted by a number of factors, including the following:

- our ability to generate and increase revenue;
- fluctuations in gross margins, operating expenses and net results; and
- fluctuations in working capital.

Our primary short-term capital needs, which are subject to change, include expenditures related to:

- expansion of our sales, marketing and distribution activities; and
- expansion of our research and development activities.

17

We regularly evaluate our cash requirements for current operations, commitments, capital requirements and business development transactions, and we may elect to raise additional funds for these purposes in the future.

### Cash flows

The following table provides a summary of our cash flows for the periods indicated:

*(unaudited)*

| Net Cash Provided by (Used In): | For the Three Months Ended June 30, 2019 | 2018 |
| --- | ---: | ---: |
| Operating Activities | $(941,596) | $(4,689,893) |
| Investing Activities | (2,729,144) | 647,890 |
| Financing Activities | 2,620,484 | 1,969,311 |
| **Total** | $(1,050,256) | $(2,072,692) |

### Cash flows from operating activities

Net cash used in operating activities was $941,596 for the six months ended June 30, 2019, consisting of a net loss of $2,008,710 partially offset by a decrease in net operating assets of $364,124 and by non-cash charges of $702,990. The decrease in net operating assets was primarily due to a decrease in accounts receivable net of an increase in inventory, offset by a decrease in accounts payables and accrued expenses net of an increase in deferred revenue. Non-cash charges consisted of stock compensation expense, depreciation and amortizations and warranty provision. Net cash used in operating activities was $4,689,893 for the six months ended June 30, 2018, primarily due to the operating loss and the increase in accounts receivable.

### Cash flows from investing activities

Net cash used by investing activities was $2,729,144 mostly due to net investments in debt securities held-to-maturity for $2,499,718 during the six months ended June 30, 2019. Net cash provided by investing activities was $647,890 for the six months ended June 30, 2018 due to the maturity of debt securities held-to-maturity of $1,104,635, partially offset by $456,745 for acquisition of property and equipment.

### Cash flows from financing activities

Net cash provided by financing activities was $2,620,484 during the six months ended June 30, 2019 mostly from the exercise of 405,813 investor warrants. Net cash provided by financing activities was $1,969,311 during the six months ended June 30, 2018, mainly from $2,000,663 in borrowing from our revolving credit facility.

### Capital resources

On November 6, 2017, we filed a universal shelf registration statement to offer up to $20 million of our securities. In September 2018, we issued and sold 2,536,764 shares of our common stock in a follow-on public offering at a price of $6.80 per share, for aggregate offering proceeds of $17.25 million. We were previously limited in the amount of securities we were able to offer under a shelf registration statement pursuant to the SEC’s “baby shelf” rules. These rules previously restricted our issuance of securities under a shelf registration statement to one-third of our public float within a 12-month period. Because our public float exceeded $75 million within 60 days prior to the filing of our 2018 annual report on Form 10-K, we are not presently subject to this limitation with regard to our existing shelf registration statement. However, we must re-determine the applicability of the limitation at the time of filing another shelf registration statement and at the time of filing an annual report on Form 10-K (with respect to any shelf registration on file with the SEC at the time of filing). Depending on our public float in the future, we may again become subject to this limitation.

### Indebtedness

Please see Note 4 to the financial statements.

### Off-Balance Sheet Arrangements

We did not have during the periods presented, and do not currently have, any off-balance sheet arrangements.

### Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S., or GAAP. We have identified certain accounting policies as critical to understanding our financial condition and results of our operations. For a detailed discussion on the application of these and other accounting policies, see the notes to our financial statements and our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, for the year ended December 31, 2018.

### JOBS Act

We qualify as an “emerging growth company” pursuant to the provisions of the JOBS Act. For as long as we are an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, reduced disclosure obligations relating to the presentation of financial statements in Management’s Discussion and Analysis of Financial Condition and Results of Operations, exemptions from the requirements of holding advisory “say-on-pay” votes on executive compensation and shareholder advisory votes on golden parachute compensation. We have availed ourselves of the reduced reporting obligations in this Quarterly Report on Form 10-Q, and expect to continue to avail ourselves of the reduced reporting obligations available to emerging growth companies in future filings.

In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to “opt out” of such extended transition period, and as a result, we plan to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

## Controls and procedures

As filed, 902 characters.

### Evaluation of Disclosure Control and Procedures

As of June 30, 2019, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of June 30, 2019, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.

### Changes in Internal Control over Financial Reporting

There have been no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,058 characters.

An investment in our securities involves risks. You should carefully consider the risk factors as previously disclosed in our Form 10-K filed with the SEC for the year ended December 31, 2018, as updated in our subsequent quarterly reports, together with the other information in this Quarterly Report on Form 10-Q, including the financial statements and related notes, before deciding whether to purchase, hold, or sell our securities. The occurrence of any of these risks could harm our business, financial condition, or results of operations or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. There have been no material changes to the risk factors as previously disclosed in our Form 10-K filed with the SEC for the year ended December 31, 2018, the discussion of which is specifically incorporated by reference into this Quarterly Report on Form 10-Q.

Filed Aug 12, 2019.
Source: SEC EDGAR, the filing index for accession 0001213900-19-015316. Last ingested by Listed: Nov 14, 2026, 13:10 ET. No prices; not investment advice.
